About Mabtech

Capture | Detect | Discover

Mabtech is a Swedish biotech company founded in 1986. Our mission is to aid researchers to reach new frontiers and develop novel therapies, by supplying optimal immunoassays based on high-quality monoclonal antibodies and instruments.

We develop and produce a wide range of monoclonal antibodies to cytokines and immunoglobulins. By selecting optimal matching pairs of capture and detection antibodies, we develop dependable sandwich assays such as ELISA, ELISpot and FluoroSpot kits. These kits are used to study immune responses in e.g. infectious disease, cancer, allergy, transplantation and as monitoring tools in vaccine trials.

Our readers deliver unbiased spot analysis by combining an innovative algorithm with state-of-the-art hardware. Mabtech IRIS is our next-generation 4-color FluoroSpot/ELISpot reader enabling reliable multiplexing. Mabtech ASTOR is a reader with the same innovative and user-friendly technology for labs performing only ELISpot.

Facts about Mabtech
  • Focus : Manufacturer
  • Industry : Biotechnology

Here you will find Mabtech AB

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous